These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 8513607

  • 1. Recombinant human erythropoietin (rhEPO) treatment potentiates growth hormone (GH) response to growth hormone releasing hormone (GHRH) stimulation in hemodialysis patients.
    Cremagnani L, Cantalamessa L, Orsatti A, Vigna L, Vallino F, Buccianti G.
    Clin Nephrol; 1993 May; 39(5):282-6. PubMed ID: 8513607
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Increased growth hormone response to growth hormone releasing hormone induced by erythropoietin in uraemic patients.
    Cantalamessa L, Cremagnani L, Orsatti A, Vigna L, Buccianti G.
    Clin Endocrinol (Oxf); 1991 Jan; 34(1):85-9. PubMed ID: 2004477
    [Abstract] [Full Text] [Related]

  • 5. Growth hormone and cortisol secretion before and after erythropoietin therapy in CAPD patients.
    Diez JJ, Iglesias P, Sastre J, Gomez-Pan A, Mendez J, Bajo MA, Selgas R.
    Adv Perit Dial; 1994 Jan; 10():275-81. PubMed ID: 7999845
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Long-term effects of recombinant human erythropoietin therapy on growth hormone secretion in uremic patients undergoing peritoneal dialysis.
    Díez JJ, Iglesias P, Sastre J, Aguilera A, Bajo MA, Méndez J, Gómez Pan A, Selgas R.
    Metabolism; 1999 Feb; 48(2):210-6. PubMed ID: 10024084
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
    Nakamoto H, Mimura T, Honda N.
    Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Inhibitory action on GHRH-induced GH secretion of chronic tamoxifen treatment in breast cancer.
    De Marinis L, Mancini A, Izzi D, Bianchi A, Giampietro A, Fusco A, Liberale I, Rossi S, Valle D.
    Clin Endocrinol (Oxf); 2000 Jun; 52(6):681-5. PubMed ID: 10848871
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Influence of recombinant human erythropoietin on growth hormone responses to growth hormone releasing hormone in uremic patients.
    Díez JJ, Iglesias P, Selgas R.
    Clin Nephrol; 1994 Feb; 41(2):119. PubMed ID: 8004829
    [No Abstract] [Full Text] [Related]

  • 20. Differences in reproducibility and peak growth hormone responses to repeated testing with various stimulators in healthy adults.
    Hoeck HC, Jakobsen PE, Vestergaard P, Falhof J, Laurberg P.
    Growth Horm IGF Res; 1999 Feb; 9(1):18-24. PubMed ID: 10207504
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.